A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Dennis L. Citrin; Merrill S. Kies; Carl‐Bertil ‐B Wallemark; Jan Khandekar; Edward Kaplan; Fernando Camacho; Richard Lind

doi:10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Dennis L. Citrin, Merrill S. Kies, Carl‐Bertil ‐B Wallemark, Jan Khandekar, Edward Kaplan, Fernando Camacho, Richard Lind

Oncology

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

Original language	English (US)
Pages (from-to)	457-460
Number of pages	4
Journal	Cancer
Volume	56
Issue number	3
DOIs	https://doi.org/10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7
State	Published - Aug 1 1985

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

Cite this

@article{e1b40addd22b45f98a9d193da7b03fb3,

title = "A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer",

abstract = "Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.",

author = "Citrin, {Dennis L.} and Kies, {Merrill S.} and Wallemark, {Carl‐Bertil ‐B} and Jan Khandekar and Edward Kaplan and Fernando Camacho and Richard Lind",

year = "1985",

month = aug,

day = "1",

doi = "10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7",

language = "English (US)",

volume = "56",

pages = "457--460",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

AU - Citrin, Dennis L.

AU - Kies, Merrill S.

AU - Wallemark, Carl‐Bertil ‐B

AU - Khandekar, Jan

AU - Kaplan, Edward

AU - Camacho, Fernando

AU - Lind, Richard

PY - 1985/8/1

Y1 - 1985/8/1

N2 - Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

AB - Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

UR - http://www.scopus.com/inward/record.url?scp=0021840733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021840733&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

DO - 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

M3 - Article

C2 - 4005808

AN - SCOPUS:0021840733

SN - 0008-543X

VL - 56

SP - 457

EP - 460

JO - Cancer

JF - Cancer

IS - 3

ER -

A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this